{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06351124",
            "orgStudyIdInfo": {
                "id": "00005294"
            },
            "organization": {
                "fullName": "University of Texas at Austin",
                "class": "OTHER"
            },
            "briefTitle": "Beta-Hydroxybutyrate Feasibility Treating IBD",
            "officialTitle": "Feasibility of Beta-hydroxybutyrate Supplementation to Reduce Inflammation in Patients With Inflammatory Bowel Disease",
            "acronym": "BHB",
            "therapeuticArea": [
                "Immunology and Rheumatology",
                "Gastroenterology"
            ],
            "study": "beta-hydroxybutyrate-feasibility-treating-ibd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-26",
            "studyFirstSubmitQcDate": "2024-04-01",
            "studyFirstPostDateStruct": {
                "date": "2024-04-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Texas at Austin",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial aims to understand the feasibility of patients taking ketone body supplement beta-hydroxybutyrate (BHB) for 4 weeks with a confirmed diagnosis of Crohn's disease and starting new therapy for active disease.\n\nThe main questions it aims to answer are:\n\n* BHB supplementation will be feasible and acceptable to patients.\n* BHB supplementation will be associated with a reduction in systemic inflammation.\n* BHB supplementation will be associated with a reduction in pro-inflammatory bacterial colonies.\n\nParticipants will:\n\n* Take 3 capsules x 3 times per day for 4 weeks.\n* Document food consumption using a 24-hour food recall questionnaire.\n* Provide blood and fecal samples twice, at the beginning of the study and the 4-week mark.\n\nResearchers will compare the group taking the ketone body supplement and the group not taking the supplement to see if the supplement provides relief of symptoms suffered from Crohn's disease.",
            "detailedDescription": "A clinical trial designed to determine the feasibility of prebiotic supplementation with beta-hydroxybutyrate (BHB) in Crohn's patients in a prospective, open-label pilot trial and to assess the association between BHB supplementation and changes in the microbiome, inflammation, and markers of disease severity in Crohn's patients in a prospective pre-/post-study design."
        },
        "conditionsModule": {
            "conditions": [
                "Crohn's Disease",
                "Inflammatory Bowel Diseases"
            ],
            "keywords": [
                "Beta-hydroxybutyrate (BHB)",
                "proinflammatory immune cells",
                "gut bacteria",
                "ketone body",
                "ketogenesis",
                "gut barrier integrity",
                "inflammation",
                "digestive health"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This will be a prospective, open-label, randomized, two-arm pilot trial of adults",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Eligible consenting patients will be randomized to either standard of care therapy (control) vs standard of care therapy plus BHB supplementation (intervention). BHB will be supplemented as a capsule taken orally three times daily for four weeks for those randomized to the intervention arm."
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "standard of care therapy (control)",
                    "type": "NO_INTERVENTION",
                    "description": "Arm does not receive the BHB supplement"
                },
                {
                    "label": "Standard of care therapy plus BHB supplementation (intervention).",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Arm does receives the BHB supplement",
                    "interventionNames": [
                        "Biological: Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's",
                    "description": "Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.",
                    "armGroupLabels": [
                        "Standard of care therapy plus BHB supplementation (intervention)."
                    ],
                    "otherNames": [
                        "BHB Feasibility"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Ability to enroll patients who meet the inclusion criteria within the target time frame",
                    "description": "Number of patients recruited",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Adherence to proposed study timelines and anticipated study costs",
                    "description": "Alignment of predicted timeline and costs to real timeline and costs",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Patient adherence to the intervention",
                    "description": "How many dosages do participants miss following the regiment.",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Microbial Diversity",
                    "description": "Changes in the microbial diversity and proportional abundance of major bacterial taxa at four weeks compared to baseline",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "BHB Blood Levels",
                    "description": "Changes in BHB serum levels at baseline compared to 4 weeks",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Gastrointestinal Symptoms",
                    "description": "Changes in (GI PROMIS score)",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Pain intensity (Patient-Reported Outcomes Measurement Information System (PROMIS)",
                    "description": "Changes in (PROMIS-29), PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain.\n\nScales:\n\nPhysical Function 5-1: 5.without any difficulty, 4.with a little difficulty, 3.with some difficulty, 2.with much difficulty, 1.unable Anxiety \\& Depression 1-5: 1.Never, 2.Rarely, 3.Sometimes, 4.Often, 5.Always Fatigue 5-1: 1.Not at all, 2.A little bit, 3.Somewhat, 2.Quite a bit, 1.Very much Sleep Disturbance 5-1: 5.Very poor, 4.poor 3. fair, 2.Good, 1. very good Ability to participate in social roles and activities 5-1: 5.Never, 4.Rarely, 3.Sometimes, 2.Usually, 1.Always Pain interference 1-5: 1. Not at all, 2.A little bit, 3.Somewhat, 4.Quite a bit, 5.Very much",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Clinical Response",
                    "description": "Improved disease activity (reduction in fecal calprotectin by 50%)",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Systemic Inflammation",
                    "description": "changes measured by C-reactive protein",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Adverse Events",
                    "description": "Adverse events related to the intervention. Outcomes will be assessed at four weeks follow-up",
                    "timeFrame": "4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years of age\n* Confirmed diagnosis of Crohn's disease\n* Active disease defined as either a fecal calprotectin \\&amp;amp;gt;250 \u00b5g/g or active disease on endoscopy within the prior 3 months\n* Starting a new therapy defined as a biologic (anti-TNF, anti-integrin, IL-12/23, or IL-23) or small molecule therapy (JAK inhibitor, S1P receptor modulator)\n* Willing to provide consent for participation.\n* Managed at UT Digestive Health Clinic.\n\nExclusion Criteria:\n\n* Any current or recent (within 4 weeks) use of BHB supplement\n* Currently or recently (within 4 weeks) following a ketogenic diet\n* Currently or recently (within 4 weeks) following an intermittent fasting diet\n* Any recent antibiotic use (within 3 months)\n* Recent infection with C. difficile (within 6 months)\n* Current or recent (within 4 weeks) daily use of acid-suppressing therapy (proton pump inhibitor or H2 receptor blocker)\n* Current or recent use (within four weeks) of non-dietary probiotic supplements\n* Unwilling to provide signed consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Linda A. Feagins, Associate Professor, MD",
                    "role": "CONTACT",
                    "phone": "512-495-5641",
                    "email": "linda.feagins@austin.utexas.edu"
                },
                {
                    "name": "Juan P Robayo, Research Program Manager, MPH",
                    "role": "CONTACT",
                    "phone": "407-928-3556",
                    "email": "juan.robayo@austin.utexas.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Linda A. Feagins, Associate Professor, MD",
                    "affiliation": "University of Texas at Austin",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Texas at Austin",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78712",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michelle Stickler, Associate Vice President, DEd",
                            "role": "CONTACT",
                            "phone": "512-475-6323",
                            "email": "m.stickler@austin.utexas.edu"
                        },
                        {
                            "name": "Thomas Street, Executive Director",
                            "role": "CONTACT",
                            "phone": "512 495 5142",
                            "email": "thomas.street@austin.utexas.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003424",
                    "term": "Crohn Disease"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000015212",
                    "term": "Inflammatory Bowel Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005759",
                    "term": "Gastroenteritis"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M6638",
                    "name": "Crohn Disease",
                    "asFound": "Crohn's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17917",
                    "name": "Inflammatory Bowel Diseases",
                    "asFound": "Inflammatory Bowel Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "asFound": "Bowel Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8875",
                    "name": "Gastroenteritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        }
    },
    "hasResults": false
}